Abstract:Importance: Approximately 125 million people worldwide have psoriasis. Patients with psoriasis experience substantial morbidity and increased rates of inflammatory arthritis, cardiometabolic diseases, and mental health disorders. Observations: Plaque psoriasis is the most common variant of psoriasis. The most rapid advancements addressing plaque psoriasis have been in its pathogenesis, genetics, comorbidities, and biologic treatments. Plaque psoriasis is associated with a number of comorbidities including psoriatic arthritis, cardiometabolic diseases, and depression. For patients with mild psoriasis, topical agents remain the mainstay of treatment, and they include topical corticosteroids, vitamin D analogues, calcineurin inhibitors, and keratolytics. The American Academy of Dermatology-National Psoriasis Foundation guidelines recommend biologics as an option for first-line treatment of moderate to severe plaque psoriasis because of their efficacy in treating it and acceptable safety profiles. Specifically, inhibitors to tumor necrosis factor α (TNF-α) include etanercept, adalimumab, certolizumab, and infliximab. Other biologics inhibit cytokines such as the p40 subunit of the cytokines IL-12 and IL-13 (ustekinumab), IL-17 (secukinumab, ixekizumab, bimekizumab, and brodalumab), and the p19 subunit of IL-23 (guselkumab, tildrakizumab, risankizumab, and mirikizumab). Biologics that inhibit TNF-α, p40IL-12/23, and IL-17 are also approved for the treatment of psoriatic arthritis. Oral treatments include traditional agents such as methotrexate, acitretin, cyclosporine, and the advanced small molecule apremilast, which is a phosphodiesterase 4 inhibitor. The most commonly prescribed light therapy used to treat plaque psoriasis is narrowband UV-B phototherapy. Conclusions and relevance: Psoriasis is an inflammatory skin disease that is associated with multiple comorbidities and substantially diminishes patients' quality of life. Topical therapies remain the cornerstone for treating mild psoriasis. Therapeutic advancements for moderate to severe plaque psoriasis include biologics that inhibit TNF-α, p40IL-12/23, IL-17, and p19IL-23, as well as an oral phosphodiesterase 4 inhibitor.

Cutaneous and Systemic Psoriasis: Classifications and Classification for the Distinction

Psoriasis. Definition and Classification of A Complex Entity

Pathogenesis, Multi-Omics Research, and Clinical Treatment of Psoriasis.

Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review

Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review

547 A Variant Subtype of Psoriasis with a Unique Clinical and Immunological Characteristics

Asian Consensus on Assessment and Management of Mild to Moderate Plaque Psoriasis with Topical Therapy.

Types of Psoriasis and Their Effects on the Immune System

Psoriasis management tree based on comorbidity

Association between the systemic treatment of psoriasis and cardiovascular risk

Management of psoriasis as a systemic disease: what is the evidence?

Clinical characteristics of patients with a family history of psoriasis: an observational epidemiological study in Chinese Han population

Epidemiology and Treatment of Psoriasis: a Chinese Perspective

Metabolic Syndrome and Psoriasis: Mechanisms and Future Directions

Autoimmune Skin Conditions: Psoriasis

Signaling pathways and targeted therapies for psoriasis

Annoying Psoriasis and Atopic Dermatitis: A Narrative Review

Association of systemic inflammation index with psoriasis risk and psoriasis severity: A retrospective cohort study of NHANES 2009 to 2014

Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities

Psoriasis and Cardiovascular Risk: A Comprehensive Review

Psoriasis and its association with metabolic syndrome